NCT02683265View on ClinicalTrials.gov

A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD

PHASE4CompletedINTERVENTIONAL

Enrollment

158

Participants

Timeline

Start Date

April 25, 2016

Primary Completion Date

November 2, 2017

Study Completion Date

March 27, 2018

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

Aptensio XR

Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily

DRUG

Placebo

Placebo capsules

Trial Locations (2)

27705

Duke University Medical Center, Durham

89128

Center for Psychiatry and Behavioral Medicine Inc., Las Vegas

All Listed Sponsors

lead

Rhodes Pharmaceuticals, L.P.

INDUSTRY

NCT02683265 - A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD | Biotech Hunter | Biotech Hunter